Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 665 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Cancer in My Community: Working Toward Early Diagnosis for Children With... August 3, 2023 Different Microbiota–Host Relationships Relevant to Distinct Immune Checkpoint Blockade Regimens March 21, 2024 ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ February 10, 2019 3 ways we’re helping teenagers and young adults with cancer April 18, 2023 Load more HOT NEWS FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... Man Gets His First Haircut In 15 Years To Join The... How to Avoid Spreading Harmful Chemo Chemicals to Members of Your... Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer